Biogen和Alteogen注射剂墨水许可协议

2026-03-26 00:20

Alteogen on Wednesday announced an exclusive license agreement with Biogen (BIIB) to develop subcutaneously delivered biologics leveraging the South Korean pharma's Hybrozyme platform technology.
At the center of the agreement is ALT-B4, a human hyaluronidase product developed using the Hybrozyme platform to convert intravenously delivered biologics into more convenient and rapidly delivered subcutaneous formulations.
As part of the deal, Biogen (BIIB) will receive exclusive rights to develop and commercialize SC formulations of two ALT-B4-based biologics, as well as an option to develop a third.
In exchange, Alteogen will receive $20M upfront in connection with the first product and $10M once studies for the second product begin. The company is also eligible to receive up to $549M in milestone payments in addition to royalties on net sales.

More on Biogen